Organon (OGN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Organon (OGN) do?
Organon & Co (OGN) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Sells reproductive health products, biosimilar drugs, and off-patent branded medicines worldwide. Organon manufactures and sells women's healthcare drugs, biosimilars, and established off-patent medicines spun off. It is worth $3.65B on the market and sold $6.09B over the last year.
- Market cap
- $3.65B
- P/E ratio
- 18.1×
- Annual sales
- $6.09B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 14, 2026
Brands and businesses behind OGN
- Nexplanon: Subdermal contraceptive implant that generates revenue through physician clinic and hospital orders.
- NuvaRing: Flexible monthly hormonal birth control ring sold through retail pharmacies and family planning clinics.
- Atozet: Combination cholesterol medicine marketed in international markets to help manage cardiovascular health.
- Hadlima: Biosimilar alternative to Humira prescribed to treat various autoimmune and inflammatory diseases.
- Zetia: Cholesterol-lowering oral tablet that limits absorption of cholesterol in the digestive tract.
- Renflexis: Biosimilar biologic medicine prescribed for rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
OGN’s flags, in plain English
Each flag is a number from Organon’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Cheap on Cash Flow
Priced at 5.4 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Stupid Cash
Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 53.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Debt Is Driving
Heavy debt, 717% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about OGN
How big is Organon?
Organon’s market cap is $3.65B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $6.09B: what customers paid the company over the last year, before any costs.
What is OGN’s P/E ratio?
OGN’s P/E ratio is 18.1×. Investors pay about 18.1 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with OGN?
The company carries over eight billion dollars in long-term debt stemming from its spinoff from Merck. That is one risk on Organon’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Organon’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. OGN’s filings on SEC.gov. The Margin Monkey is research, not advice.
